Nuclear Medicine and Biology
Volume 34, Issue 7 , Pages 729-732, October 2007

Barriers to achieving commercial success for diagnostic and therapeutic radiopharmaceuticals☆

Oncology Medical Research, Biogen Idec, San Diego, CA 92130, USA

Received 26 March 2007; accepted 8 April 2007. published online 11 June 2007.

Abstract 

The concluding session of this workshop focused on barriers that might be impeding the successful transition of radiopharmaceuticals from research tools to diagnostics and therapeutics that reach commercial success. Some lessons can be learned by reviewing the technology adoption life cycle as described by Geoffrey A. Moore (Moore, GA. Crossing the chasm. New York: HarperCollins, 2002). Additionally, a review of highly successful radiopharmaceuticals suggests that achieving commercial success may require advocacy by other interested groups.

Keywords: Radiopharmaceuticals, Commercial success

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ After bench to bedside: impact on clinical outcome (February 25, 2007).

PII: S0969-8051(07)00100-X

doi:10.1016/j.nucmedbio.2007.04.004

Nuclear Medicine and Biology
Volume 34, Issue 7 , Pages 729-732, October 2007

Article Tools

* Image Usage & Resolution